Condition

Lymphoma, T-Cell clinical trials and research

• 10Clinical trials
• 1NIH research projects
• 10Countries

Newest Lymphoma, T-Cell clinical trials

All recruiting trials (10)

• Ruxolitinib maintenance after stem cell transplant for T‑cell lymphoma

  This phase II trial tests whether taking ruxolitinib after a stem cell transplant can lower the chance of relapse and graft‑versus‑host disease for people treated for T‑cell lymphoma.

  Recruiting at 2 sites Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio and 1 other locations · NCT07356245

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Investigating GCC2005 for patients with relapsed/refractory NK and T-cell malignancies

  This study is testing a new treatment called GCC2005 to see if it is safe and effective for people with certain types of blood cancers that have not responded to previous therapies.

  Recruiting at 3 sites Phase 1 GC Cell Corporation · Seoul, Seoul and 2 other locations · NCT06699771

• Comparing soquelitinib to standard treatments for certain types of relapsed T-cell lymphoma

  This study is testing if a new pill called soquelitinib can work better than regular treatments for people with certain types of relapsed T-cell lymphoma.

  Recruiting at 37 sites Phase 3 Corvus Pharmaceuticals, Inc. · Duarte, California and 36 other locations · NCT06561048

• Treatment for CD5 Positive T-cell Lymphoma using MB-105

  This study is testing a new treatment called MB-105 to see if it can help people with CD5 positive T-cell lymphoma that hasn't responded to other treatments.

  Recruiting at 9 sites Phase 2 March Biosciences Inc · San Diego, California and 11 other locations · NCT06534060

• Using PI3K inhibitors to treat relapsed indolent T/NK-cell lymphomas

  This study is testing if two new oral medications can help people with relapsed indolent T/NK-cell lymphomas feel better and improve their treatment options.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06530550

• Using Tagraxofusp to treat pediatric patients with relapsed or refractory blood cancers

  This study is testing a new drug called Tagraxofusp to see if it can help children and young adults with tough-to-treat blood cancers feel better and improve their chances of recovery.

  Recruiting at 15 sites Phase 1 Therapeutic Advances in Childhood Leukemia Consortium · Los Angeles, California and 30 other locations · NCT05476770

• Testing STP938 for patients with relapsed or refractory B-Cell and T-Cell lymphomas

  This study is testing a new drug called STP938 to see if it can help adults with tough-to-treat B-cell and T-cell lymphomas feel better.

  Recruiting at 15 sites Phase 1/2 Step Pharma, SAS · Denver, Colorado and 14 other locations · NCT05463263

• Tulmimetostat treatment for advanced solid tumors and lymphomas

  This study is testing a new treatment called Tulmimetostat to see if it can help people with advanced solid tumors and lymphomas feel better and fight their cancer.

  Recruiting at 43 sites Phase 1/2 Novartis · Tampa, Florida and 79 other locations · NCT04104776

• Durvalumab with pralatrexate, romidepsin, or oral 5‑azacitidine for peripheral T‑cell lymphoma

  This trial will test several combinations of durvalumab with pralatrexate, romidepsin, and/or oral 5‑azacitidine to find safe doses and see if they help adults with newly diagnosed or relapsed peripheral T‑cell lymphoma.

  Recruiting Phase 1/2 University of Virginia · Charlottesville, Virginia · NCT03161223

NIH-funded research (1)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Investigating how certain enzymes affect T cell immunity in lymphoma treatment

  This study is looking at how certain nutrients called branched chain amino acids affect the way immune cells called T cells work in lymphoma, with the goal of finding better ways to help these cells fight cancer during treatment.

  NIH research Des Moines Univ Osteopathic Medical Ctr · West Des Moines, United States · NIH-10291201

Related topics

Quick answers

How many Lymphoma, T-Cell clinical trials are recruiting right now?

10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (7 trials), Australia (2 trials), France (2 trials), United Kingdom (2 trials), South Korea (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 4, Phase 1/2: 3, Phase 1: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →